Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Puma Biotechnology, Inc.
ClinicalTrials.gov Identifier:
NCT01827267
First received: April 1, 2013
Last updated: September 28, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2017
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: March 2, 2016